Understanding the Significance of Hypoxia-Inducible Factors (HIFs) in Glioblastoma: A Systematic Review.

作者信息

Begagić Emir, Bečulić Hakija, Džidić-Krivić Amina, Kadić Vukas Samra, Hadžić Semir, Mekić-Abazović Alma, Šegalo Sabina, Papić Emsel, Muchai Echengi Emmanuel, Pugonja Ragib, Kasapović Tarik, Kavgić Dalila, Nuhović Adem, Juković-Bihorac Fatima, Đuričić Slaviša, Pojskić Mirza

机构信息

Department of General Medicine, School of Medicine, University of Zenica, 72000 Zenica, Bosnia and Herzegovina.

Department of Neurosurgery, Cantonal Hospital Zenica, 72000 Zenica, Bosnia and Herzegovina.

出版信息

Cancers (Basel). 2024 May 30;16(11):2089. doi: 10.3390/cancers16112089.

DOI:10.3390/cancers16112089

PMID:38893207

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11171068/

Abstract

BACKGROUND

The study aims to investigate the role of hypoxia-inducible factors (HIFs) in the development, progression, and therapeutic potential of glioblastomas.

METHODOLOGY

The study, following PRISMA guidelines, systematically examined hypoxia and HIFs in glioblastoma using MEDLINE (PubMed), Web of Science, and Scopus. A total of 104 relevant studies underwent data extraction.

RESULTS

Among the 104 studies, global contributions were diverse, with China leading at 23.1%. The most productive year was 2019, accounting for 11.5%. Hypoxia-inducible factor 1 alpha (HIF1α) was frequently studied, followed by hypoxia-inducible factor 2 alpha (HIF2α), osteopontin, and cavolin-1. Commonly associated factors and pathways include glucose transporter 1 (GLUT1) and glucose transporter 3 (GLUT3) receptors, vascular endothelial growth factor (VEGF), phosphoinositide 3-kinase (PI3K)-Akt-mechanistic target of rapamycin (mTOR) pathway, and reactive oxygen species (ROS). HIF expression correlates with various glioblastoma hallmarks, including progression, survival, neovascularization, glucose metabolism, migration, and invasion.

CONCLUSION

Overcoming challenges such as treatment resistance and the absence of biomarkers is critical for the effective integration of HIF-related therapies into the treatment of glioblastoma with the aim of optimizing patient outcomes.

摘要